188 related articles for article (PubMed ID: 10323182)
1. Heritability and segregation analysis of immune responses to specific malaria antigens in Papua New Guinea.
Stirnadel HA; Beck HP; Alpers MP; Smith TA
Genet Epidemiol; 1999; 17(1):16-34. PubMed ID: 10323182
[TBL] [Abstract][Full Text] [Related]
2. Assessment of different sources of variation in the antibody responses to specific malaria antigens in children in Papua New Guinea.
Stirnadel HA; Al-Yaman F; Genton B; Alpers MP; Smith TA
Int J Epidemiol; 2000 Jun; 29(3):579-86. PubMed ID: 10869334
[TBL] [Abstract][Full Text] [Related]
3. Strain-specific humoral response to a polymorphic malaria vaccine.
Flück C; Smith T; Beck HP; Irion A; Betuela I; Alpers MP; Anders R; Saul A; Genton B; Felger I
Infect Immun; 2004 Nov; 72(11):6300-5. PubMed ID: 15501757
[TBL] [Abstract][Full Text] [Related]
4. Evidence of HLA class II association with antibody response against the malaria vaccine SPF66 in a naturally exposed population.
Beck HP; Felger I; Barker M; Bugawan T; Genton B; Alexander N; Jazwinska E; Erlich H; Alpers M
Am J Trop Med Hyg; 1995 Sep; 53(3):284-8. PubMed ID: 7573714
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity of a recombinant malaria vaccine candidate, domain I+II of AMA-1 ectodomain, from Indian P. falciparum alleles.
Lalitha PV; Biswas S; Pillai CR; Saxena RK
Vaccine; 2008 Aug; 26(35):4526-35. PubMed ID: 18590786
[TBL] [Abstract][Full Text] [Related]
6. Humoral immune responses to the Plasmodium falciparum antigen Pf155 RESA in adults with differential clinical conditions from an Indian zone where malaria is endemic.
Biswas S; Rao DN; Roy A; Yadav RP; Ghosh SK; Kabilan L
Southeast Asian J Trop Med Public Health; 1995 Jun; 26(2):219-27. PubMed ID: 8629049
[TBL] [Abstract][Full Text] [Related]
7. Assessment of the role of the humoral response to Plasmodium falciparum MSP2 compared to RESA and SPf66 in protecting Papua New Guinean children from clinical malaria.
al-Yaman F; Genton B; Anders R; Taraika J; Ginny M; Mellor S; Alpers MP
Parasite Immunol; 1995 Sep; 17(9):493-501. PubMed ID: 8552419
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of two long synthetic merozoite surface protein 2 peptides as malaria vaccine candidates.
Flueck C; Frank G; Smith T; Jafarshad A; Nebie I; Sirima SB; Olugbile S; Alonso P; Tanner M; Druilhe P; Felger I; Corradin G
Vaccine; 2009 May; 27(20):2653-61. PubMed ID: 19428875
[TBL] [Abstract][Full Text] [Related]
9. Do antibody responses to malaria vaccine candidates influenced by the level of malaria transmission protect from malaria?
Nebie I; Tiono AB; Diallo DA; Samandoulougou S; Diarra A; Konate AT; Cuzin-Ouattara N; Theisen M; Corradin G; Cousens S; Ouattara AS; Ilboudo-Sanogo E; Sirima BS
Trop Med Int Health; 2008 Feb; 13(2):229-37. PubMed ID: 18304269
[TBL] [Abstract][Full Text] [Related]
10. Effect of the malaria vaccine Combination B on merozoite surface antigen 2 diversity.
Flück C; Schöpflin S; Smith T; Genton B; Alpers MP; Beck HP; Felger I
Infect Genet Evol; 2007 Jan; 7(1):44-51. PubMed ID: 16647307
[TBL] [Abstract][Full Text] [Related]
11. A bicistronic DNA vaccine containing apical membrane antigen 1 and merozoite surface protein 4/5 can prime humoral and cellular immune responses and partially protect mice against virulent Plasmodium chabaudi adami DS malaria.
Rainczuk A; Scorza T; Spithill TW; Smooker PM
Infect Immun; 2004 Oct; 72(10):5565-73. PubMed ID: 15385453
[TBL] [Abstract][Full Text] [Related]
12. Allele specificity of naturally acquired antibody responses against Plasmodium falciparum apical membrane antigen 1.
Cortés A; Mellombo M; Masciantonio R; Murphy VJ; Reeder JC; Anders RF
Infect Immun; 2005 Jan; 73(1):422-30. PubMed ID: 15618180
[TBL] [Abstract][Full Text] [Related]
13. Familial correlation of immunoglobulin G subclass responses to Plasmodium falciparum antigens in Burkina Faso.
Aucan C; Traoré Y; Fumoux F; Rihet P
Infect Immun; 2001 Feb; 69(2):996-1001. PubMed ID: 11159995
[TBL] [Abstract][Full Text] [Related]
14. Relationship between humoral response to Plasmodium falciparum merozoite surface antigen-2 and malaria morbidity in a highly endemic area of Papua New Guinea.
al-Yaman F; Genton B; Anders RF; Falk M; Triglia T; Lewis D; Hii J; Beck HP; Alpers MP
Am J Trop Med Hyg; 1994 Nov; 51(5):593-602. PubMed ID: 7985752
[TBL] [Abstract][Full Text] [Related]
15. Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine.
Lalvani A; Moris P; Voss G; Pathan AA; Kester KE; Brookes R; Lee E; Koutsoukos M; Plebanski M; Delchambre M; Flanagan KL; Carton C; Slaoui M; Van Hoecke C; Ballou WR; Hill AV; Cohen J
J Infect Dis; 1999 Nov; 180(5):1656-64. PubMed ID: 10515829
[TBL] [Abstract][Full Text] [Related]
16. Class II restriction in mice to the malaria candidate vaccine ring infected erythrocyte surface antigen (RESA) as synthetic peptides or as expressed in recombinant vaccinia.
Lew AM; Langford CJ; Pye D; Edwards S; Corcoran L; Anders RF
J Immunol; 1989 Jun; 142(11):4012-6. PubMed ID: 2715642
[TBL] [Abstract][Full Text] [Related]
17. Genetic analysis of IgG subclass responses against RESA and MSP2 of Plasmodium falciparum in adults in Papua New Guinea.
Stirnadel HA; Beck HP; Alpers MP; Smith TA
Epidemiol Infect; 2000 Feb; 124(1):153-62. PubMed ID: 10722143
[TBL] [Abstract][Full Text] [Related]
18. Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research.
Polhemus ME; Magill AJ; Cummings JF; Kester KE; Ockenhouse CF; Lanar DE; Dutta S; Barbosa A; Soisson L; Diggs CL; Robinson SA; Haynes JD; Stewart VA; Ware LA; Brando C; Krzych U; Bowden RA; Cohen JD; Dubois MC; Ofori-Anyinam O; De-Kock E; Ballou WR; Heppner DG
Vaccine; 2007 May; 25(21):4203-12. PubMed ID: 17442466
[TBL] [Abstract][Full Text] [Related]
19. Comparison of cellular and humoral responses to recombinant protein and synthetic peptides of exon2 region of Plasmodium falciparum erythrocyte membrane protein1 (PfEMP1) among malaria patients from an endemic region.
Das P; Grewal JS; Mahajan B; Chauhan VS
Parasitol Int; 2007 Mar; 56(1):51-9. PubMed ID: 17258500
[TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of a three-component blood-stage malaria vaccine in adults living in an endemic area of Papua New Guinea.
Genton B; Al-Yaman F; Anders R; Saul A; Brown G; Pye D; Irving DO; Briggs WR; Mai A; Ginny M; Adiguma T; Rare L; Giddy A; Reber-Liske R; Stuerchler D; Alpers MP
Vaccine; 2000 May; 18(23):2504-11. PubMed ID: 10775784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
